Streptozotocin (STZ) 鏈脲佐菌素簡介：

產(chǎn)品名稱 ：鏈脲佐菌素; 鏈氮霉素; 鏈脲菌素; 2-脫氧-2-(((甲基亞硝基氨基)羰基)-氨基)-D-吡喃葡萄糖

英文名稱：STREPTOZOTOCIN ,2-desoxy-2-(3-methyl-3-nitrosoureido)-d-glucopyranose; 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-d-glucose

產(chǎn)品介紹：鏈脲佐菌素是一種N-亞硝基化合物, 是一種氨基葡萄糖，是一種DNA烷基化試劑。作為胰島中一氧化氮供體,誘導分泌胰島素的細胞死亡，產(chǎn)生糖尿病的動物模型。屬于強有力誘導染色體斷裂的DNA甲基化劑。能通過GLUT2葡萄糖轉(zhuǎn)運蛋白（GLUT2 glucose transport protein）獨自進入細胞。對表達GLUT2葡萄糖轉(zhuǎn)運子的神經(jīng)內(nèi)分泌腫瘤細胞株有細胞毒性。對胰腺胰島內(nèi)胰島素誘發(fā)的β-細胞具毒性。

性能

溶解性：鏈脲菌素溶于水，溶于乙醇

Streptozotocin (STZ) 鏈脲佐菌素用途： 生化實驗研究，廣泛應用于分子生物學，藥理學等科研方面。一種含N-亞硝基的化合物，在胰腺胰島充當一氧化氮的供體；誘導產(chǎn)生糖尿病動物模式的胰島素分泌細胞的死亡。高效DNA甲基化試劑，能誘發(fā)染色體斷裂。鏈脲菌素為Stre.achromogenes Uar.128產(chǎn)生的亞硝脲類抗生素，它與脂溶性的亞硝脲不同，在氯乙基處是一個甲基，在分子的另一端是一個氨基糖。STZ可自行分解活潑的甲基正碳離子，與DNA呈鏈間交叉連結，從而使DNA烷化，但其烷化作用比其他，而其代謝產(chǎn)物甲基亞硝脲的烷化作用較其STZ強3~4倍。STZ在體內(nèi)可形成異氰酸鹽。從而與核酸蛋白結合，抑制DNA多聚酶活力，使受損的DNA難于修復。在進行抗腫瘤研究過程中發(fā)現(xiàn)，STZ可使鼠類的血糖升高，在犬及猴可致糖尿病，且呈*性。STZ的糖尿病作用具有種屬差異性，在豚鼠不引起，在人亦不引起。其致糖尿病機制主要是由于胰島細胞中菸酰胺腺嘌呤（DNA）含量減少，STZ分子中的葡萄糖基可使STZ進入胰島β細胞，引起β細胞核內(nèi)形態(tài)變化，使其染色體凝集、伸長和濃縮。對表達GLUT2葡萄糖轉(zhuǎn)運體（GLUT2 glucose transporter）的神經(jīng)內(nèi)分泌腫瘤細胞系具細胞毒性。

醫(yī)學研究上鏈脲佐菌素用于誘導Type 1 糖尿病。
儲存條件 ：2～8℃

Sigma相關資料如下

Product: ：Streptozocin

Molecular Weight: 265.2

Molecular Formula: C8H15N3O7

Code: 0130

CAS：18883-66-4

PHYSICAL DESCRIPTION:

Appearance: White to yellow powder

Molecular formula: C8H15N3O7

Molecular weight: 265.2

Melting point: Decomposes at 115EC if anhydrous.1 Although Sigma does not determine a value, water

content should be # 3%.2

EmM(228nm) = 6.36 (ethanol)

Optical rotation: +39E(equilibrium of a, ß anomers in H2O, 25EC)1

Please consult the Material Safety Data Sheet about the properties of this material as a potential carcinogen, mutagen and toxic chemical.

STORAGE / STABILITY AS SUPPLIED:

If the product is stored frozen and protected from moisture and air, it is stable for approximay 2 years.(After 12 year, a sample changed from 94.9% a-anomer to 94.7%, as measured by HPLC.)2

SOLUBILITY / SOLUTION STABILITY:

Streptozotocin is soluble in water, the lower alcohols and in ketones. This product dissolves in water at 50mg/mL to give a light yellow solution, from clear to slightly hazy. Aqueous solutions rapidly undergo mutarotation to an equilibrium mixture of alpha- and beta-anomers.

STREPTOZOTOCIN MIXED ANOMERS

Sigma No. S0130

SOLUBILITY / SOLUTION STABILITY:

Maximum solution stability is at pH 4, with stability decreasing rapidly at higher or lower pH. Freshly prepared solutions are clear and have a light straw color. On standing, they take on a yellow to brown color and effervesce, indicating decomposition.2,3 Solutions should be prepared just before use,since the product is unstable.

GENERAL REMARKS:

This product is an antineoplastic antibiotic produced by the growth of a Streptomyces achromogenes variant or by synthesis. It may affect glucose metabolism. It is used mainly in the treatment of pancreatic (isletcell) tumors.4 Burcelin et al. used intravenous injection of streptozotocin in rats at a dose of 65 mg/kg body weight to induce diabetes (using cold 0.1 M citrate buffer pH 4.5).5 In rats and dogs, diabetes was induced using intravenous dosage of 50 mg/kg (using 1-2% w/v solutions in saline buffered with citrate dextrosesolution at pH 5.0).3 It has been used for the treatment of malignant insulinoma; very precise assays for thisdrug have been developed.6

Streptozotocin does not cross the blood-brain barrier, but its metabolites are found in cerebral spinal fluid.4 Its biological half-life in cell culture medium was shown to be approximay 19 minutes.7

The antileukemic effects of streptozotocin and its analogs have been reported.8 Streptozotocin has been shown to be a potent methylating agent that reacts with DNA in vitro to form methylated purines.9 A reviewarticle addressed a number of antineoplastic antibiotics, including streptozotocin.10 A useful handbookoffered several references for use in animal studies.11

REFERENCES:

1. Merck Index, 12th ed., #8991 (1996).

2. Sigma quality control or supplier information.

3. Rakieten, N. et al., Cancer Chemother. Reports, No. 29, 91-98 (1963).

4. Martindale: The Extra Pharmacopoeia, 29th ed., (Pharmaceutical Press, 1989), p. 649.

5. Burcelin, R. et al., Biochem. J., 291, 109-113 (1993).

6. Oles, P.J., J. Pharmaceutical Sci., 67 (9), 1300 (1978).

7. Jensen, E.M. et al., J. Natl. Cancer Inst., 59, 941-944 (1977).

8. Bhuyan, B.K. et al., Cancer Chemother. Reports, Part 1, 45 (6), 709-720 (1972).

9. Bennett, R.A. and Pegg, A.E., Cancer Research, 41, 2756-2790 (1981).

10. Cheng, C.C. and K.-Y. Zee-Cheng, J. Pharmaceutical Sci., 61, 485-501 (1972).

11. Drug Dosage in Laboratory Animals: A Handbook , 3rd ed., R.E. Borchard et al., eds. (CRC Press,

1992).

Sigma warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particularuse. Additional terms and conditions may apply. Please see reverse side of the invoice orpacking slip.

Streptozotocin (STZ) 鏈脲佐菌素訂購信息：

上海懋康生物科技有限公司是一家涉足于生命科學和生物技術領域研究的試劑、儀器和實驗室消耗品與實驗服務工作，主要從事細胞生物學、植物學、分子生物學、免疫學、生物化學、蛋白組學。生物制藥與診斷試劑研發(fā)生產(chǎn)等領域。 本公司秉承“以人為本，以誠為信、合同守信”的經(jīng)營理念。堅持"品質(zhì)保障"的原則為廣大客戶提供優(yōu)質(zhì)產(chǎn)品。

Streptozotocin （STZ） 鏈脲佐菌素 糖尿病建模

Streptozotocin （STZ） 鏈脲佐菌素 糖尿病建模